Page last updated: 2024-11-10

seocalcitol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

seocalcitol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5288149
CHEMBL ID1908376
SCHEMBL ID12028975
MeSH IDM0364734

Synonyms (36)

Synonym
(22e,24e)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homovitamin d3 / (22e,24e)-1alpha,25-dihydroxy-26,27-dimethyl-22,23,24,24a-tetradehydro-24a-homocholecalciferol
(5z,7e,22e,24e)-(1s,3r)-26,27-dimethyl-24a-homo-9,10-seco-5,7,10(19),22,24-cholestapentaene-1,3,25-triol
LMST03020449
HY-32341
gtpl2777
cb-1089 ,
eb-1089
(5z,7e,22e,24e)-24a,26a,27a-trihomo-9,10-secocholesta-5,7,10(19),22,24-pentaene-1alpha,3beta,25-triol
eb1089
1(s),3(r)-dihydroxy-20(r)-(5'-ethyl-5'-hydroxyhepta-1'(e),3'(e)-dien-1'-yl)-9,10-secopregna-5(z),7(e),10(19)-triene
seocalcitol [inn:ban]
1,3-cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4h-inden-4-ylidene)ethylidene)-4-methylene-, (1r-(1alpha(1r*,2e,4e),3abeta,4e(1r*,3s*,5z),7aalpha))-
1,3-cyclohexanediol, 5-((2e)-((1r,3as,7ar)-1-((1r,2e,4e)-6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4h-inden-4-ylidene)ethylidene)-4-methylene-, (1r,3s,5z)-
seocalcitol
DB04258
(1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r,3e,5e)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
q0oz0d9223 ,
unii-q0oz0d9223
CHEMBL1908376
CS-0398
seocalcitol [mi]
seocalcitol [mart.]
seocalcitol [who-dd]
seocalcitol [inn]
LVLLALCJVJNGQQ-SEODYNFXSA-N
AKOS024457918
SCHEMBL12028975
(1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(1r,2e,4e)-6-ethyl-6-hydroxy-1-methyl-2,4-octadien-1-yl]-octahydro-7?-methyl-4h-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol
(1r,3s,5z)-5-((2e)-((1r,3as,7ar)-1-((1r,2e,4e)-6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4h-inden-4-ylidene)ethylidene)-4-methylene-1,3-cyclohexanediol
eb1089, >=98% (hplc)
mfcd00871599
(1r,3s,5z)-5-[(2e)-2-{(1r,3as,7ar)-1-[(1r,2e,4e)-6-ethyl-6-hydroxy-1-methylocta-2,4-dien-1-yl]-7a-methyloctahydro-4h-inden-4-ylidene}ethylidene]-4-methylidenecyclohexane-1,3-diol (non-preferred name)
Q27088781
MS-28286
DTXSID601025740
(1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(1r,2e,4e)-6-ethyl-6-hydroxy-1-methyl-2,4-octadien-1-yl]-octahydro-7a-methyl-4h-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol

Research Excerpts

Overview

Seocalcitol (EB1089) is a vitamin D analog that has been extensively studied and shown to have profoundly reduced hypercalcemic effects.

ExcerptReferenceRelevance
"Seocalcitol (EB1089) is a vitamin D analog that has been extensively studied and shown to have profoundly reduced hypercalcemic effects."( Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study.
Akhter, J; Ghous, Z; Morris, DL; Pourgholami, MH,
)
0.85

Pharmacokinetics

ExcerptReferenceRelevance
" In rat, the pharmacokinetic profile of Seocalcitol (Cmax, AUC, Tmax, T(1/2)) was the same after single and oral administration."( Pharmacokinetics and metabolism of a vitamin D analogue (Seocalcitol) in rat and minipig.
Kissmeyer, AM; Mortensen, JT, 2000
)
0.82

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of the novel vitamin D analogue, EB1089 alone, or in combination with the retinoid, 9-cis retinoic acid (9-cis RA) on indices of apoptosis in MCF-7 breast cancer cells have been examined."( Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells.
Colston, KW; James, SY; Mackay, AG, 1995
)
0.29
" We tested the growth inhibitory activity of ketoconazole combined with 1,25-dihydroxyvitamin D3 (calcitriol) and with the vitamin D analogue EB 1089 in a preclinical model of prostate cancer."( Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells.
Feldman, D; Hsu, JY; Peehl, DM; Seto, E, 2002
)
0.31
"Clonal assays with primary cultures of human prostatic cancer cells were performed to test anti-proliferative effects of ketoconazole alone or in combination with calcitriol or EB 1089."( Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells.
Feldman, D; Hsu, JY; Peehl, DM; Seto, E, 2002
)
0.31

Bioavailability

The bioavailability of seocalcitol from two lipid-based formulations and a propylene glycol (PG) solution was studied in minipigs in the fasted and fed state.

ExcerptReferenceRelevance
" The bioavailability after oral administration of seocalcitol dissolved in medium chain triglyceride (MCT), long chain triglyceride (LCT), and a reference formulation containing propylene glycol (PG) was studied in vivo in rats."( Bioavailability of seocalcitol I: Relating solubility in biorelevant media with oral bioavailability in rats--effect of medium and long chain triglycerides.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2005
)
0.91
" The industrial usefulness of the developed SMEDDS was evaluated with regard to bioavailability and chemical stability using the vitamin D analogue, seocalcitol, as model compound."( Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2006
)
0.86
"The bioavailability of seocalcitol from two lipid-based formulations and a propylene glycol (PG) solution was studied in minipigs in the fasted and fed state."( Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2007
)
0.98

Dosage Studied

A lymph cannulated conscious rat model was dosed orally with (3)H-seocalcitol dissolved in either LCT or PG. Rats were treated either 6 times weekly (1 microg/kg) or by intermittent dosing to achieve the same total weekly dose.

ExcerptRelevanceReference
" Clonogenic survival studies indicate that EB 1089 shifts the dose-response curve for sensitivity to adriamycin by approximately six-fold in p53 wild-type MCF-7 cells; comparative studies in MCF-7 cells with a temperature-sensitive dominant negative p53 mutation show less than a two-fold shift in adriamycin sensitivity in the presence of EB 1089."( The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells.
Chaudhry, M; Gewirtz, DA; Gupta, M; Reardon, D; Sundaram, S, 2000
)
0.31
" The cell lines were incubated with EB 1089, a synthetic analogue vitamin of D(3), in dose-response studies."( Vitamin D receptor is expressed in pancreatic cancer cells and a vitamin D3 analogue decreases cell number.
Albrechtsson, E; Axelson, J; Höglund, M; Jonsson, T; Möller, S; Ohlsson, B, 2003
)
0.32
" In order to compare the efficacy of different dosing schedules of Seocalcitol, rats were treated either 6 times weekly (1 microg/kg) or by intermittent dosing to achieve the same total weekly dose."( Effects of Seocalcitol (EB1089) on nitrosomethyl urea-induced rat mammary tumors.
Binderup, L; Bramm, E; Colston, KW; Hamberg, KJ; Pirianov, G, 2003
)
0.94
"A lymph cannulated conscious rat model was dosed orally with (3)H-seocalcitol dissolved in either LCT or PG."( Bioavailability of seocalcitol IV: evaluation of lymphatic transport in conscious rats.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2006
)
0.9
"05) higher recovery of the dosed (3)H-seocalcitol was found in the intestinal lymph upon administration of the LCT solution (1."( Bioavailability of seocalcitol IV: evaluation of lymphatic transport in conscious rats.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2006
)
0.93
" The present study illustrates an often mentioned beneficial effect of dosing lipid-based formulations; the reduced food effect on bioavailability."( Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2007
)
0.67
" Inhibitory concentrations on cell proliferation were calculated by non-linear regression analysis using sigmoidal fitting of dose-response curves."( Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Díaz, L; Esparza-López, J; García-Becerra, R; García-Quiroz, J; González-González, ME; Ibarra-Sánchez, MJ; Larrea, F; Martínez-Reza, I; Prado-Garcia, H; Segovia-Mendoza, M, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID216996Effective concentration required for inhibition of Vitamin D3 receptor; No data2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor
AID216993Binding of compound towards human Vitamin D3 receptor was determined in vitro2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID213723Relative differentiating activity of U 937 cells when the reference value of 1,25-(OH)3D3 is defined as 1.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Conformation-function relationship of vitamin D: conformational analysis predicts potential side-chain structure.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (180)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's61 (33.89)18.2507
2000's95 (52.78)29.6817
2010's19 (10.56)24.3611
2020's5 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.45 (24.57)
Research Supply Index5.25 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (2.72%)5.53%
Reviews7 (3.80%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other172 (93.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5ug) or Placebo in the Treatment of Patients With Hepatocellular Carcinoma Not Amenable to Curative Treatment [NCT00051532]700 participants Interventional1999-09-30Terminated
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5 ug) or Placebo in Prolonging Time to Relapse Following Intended Curative Resection or Percutaneous Ablative Trea [NCT00051545]Phase 3608 participants Interventional1999-11-30Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]